Latest Development Pipeline News

Vicinity Centres reports a robust FY26 interim profit of $805.6 million, driven by strong leasing and portfolio premiumisation, including the strategic acquisition of Uptown in Brisbane.

Vicinity Centres reported a strong first half of FY26 with a statutory net profit of $805.6 million, strategic acquisitions including full ownership of Uptown Brisbane, and reaffirmed guidance for the full year.

Dexus has announced a new on-market buyback of up to 10% of its securities, aiming to address the disconnect between its market valuation and underlying asset values while maintaining capital discipline.

Dexus has reported a strong half-year result with a $348.5 million profit turnaround, robust leasing growth, and strategic capital moves including a $950 million equity raise and a 10% on-market buyback.

Vicinity Centres reported a strong first half of FY26, boosting profits and advancing key retail and mixed-use developments, while maintaining a conservative balance sheet.

Mirvac Group reported a robust half-year result with a 5% rise in operating profit and a significant boost in residential sales, underpinned by a $1 billion joint venture with Mitsubishi Estate. The company’s strategic pipeline restocking and strong leasing performance signal promising growth ahead.

HealthCo Healthcare & Wellness REIT reported resilient 1H FY26 results despite suspending distributions amid ongoing Healthscope challenges, underpinned by a diversified $1.4 billion healthcare real estate portfolio and strategic lease agreements.

Abacus Storage King has reported a 4.8% increase in statutory net profit to $71.1 million for the half-year ended December 2025, alongside a $3.7 billion asset base and plans to potentially internalise management functions.

Contact Energy has announced a $525 million equity raise to accelerate its renewable energy projects, following a strong first half of FY26 with significant profit growth and strategic acquisitions.

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

Neuren Pharmaceuticals has initiated a discretionary on-market share buy-back program of up to 5%, citing a strong cash position and undervaluation relative to internal and analyst assessments.

Actinogen Medical has received an additional $1.87 million R&D tax incentive rebate, bringing its total FY 2025 rebate to $7.36 million, while its Alzheimer’s phase 2b/3 trial progresses with promising safety results.